The Moat Index

ACADIA PHARMACEUTICALS INC

ACAD · Healthcare · $4.4B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

56/ 100
Shallow moat

The four filters

Pricing power98

Median gross margin 94.4% over 10y, very stable.

Returns on capital7

Median ROIC -47.5%, above the 9% hurdle in 20% of years.

Balance-sheet safety100

Net cash position — no leverage risk.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale
No price data
Owner earnings (normalized)
Est. intrinsic value / share
Recent price
$25.60
Discount to value
No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

18 years of fundamentals

The business, in plain English

ACADIA PHARMACEUTICALS INC booked $1.1B of revenue in FY2025 in the Healthcare sector and kept 91.7% of it as gross profit — a high-margin business by that measure. After every other cost, 36.5% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $6.4M (FY2009) to $1.1B (FY2025) — about 37.7% a year compounded over 16 years.

It earned 10.0% on invested capital in FY2025, with a median of −47.5% across 16 filed years. The Returns on Capital filter above scores it 7/100.

The balance sheet carried $32000 of total debt in FY2011. Balance-Sheet Safety scores it 100/100.

The share count rose 332.8% between FY2010 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.

Put together: Balance-Sheet Safety is the strongest of the four filters (100/100) and Returns on Capital the weakest (7/100), which is how ACAD lands at 56/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2008–FY2025 · 18 fiscal years, normalized from ACAD’s SEC filings

RevenueSales, as filed$1.1B FY2025
$0$500M$1B2008201420202025
Gross marginRevenue kept after cost of goods91.7% FY2025
0%50%100%2008201420202025
Return on invested capitalOperating profit on the capital employed10.0% FY2025
−100%0%2008201420202025
Owner earningsCash an owner could take out$386.3M FY2025
$02008201420202025

Gaps in a line mean that item isn’t in ACAD’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

3 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale56.2 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — ACAD has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#91 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #89BVS BIOVENTUS INC.56.4 out of 100, Shallow moatShallow moat
  2. #90IMAX IMAX Corporation56.3 out of 100, Shallow moatShallow moat
  3. #92TDY TELEDYNE TECHNOLOGIES INC55.9 out of 100, Shallow moatShallow moat
  4. #93BRKR BRUKER CORPORATION55.9 out of 100, Shallow moatShallow moat

Compare ACAD with its nearest peersAll Healthcare companies on the Index →

Common questions about ACAD

Does ACADIA PHARMACEUTICALS INC have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores ACADIA PHARMACEUTICALS INC (ACAD) 56.2 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 98, returns on capital 7, balance-sheet safety 100, capital discipline 24.
How has ACAD's Moat Score changed over time?
The record logs 3 readings since Jul 17, 2026; the latest reads 56.2 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.
Embed this score on your site

One iframe, no script. The badge shows ACAD’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/ACAD"
  width="340" height="150" style="border:0"
  title="ACAD Moat Score — The Moat Index"
  loading="lazy"></iframe>
ACADIA PHARMACEUTICALS INC (ACAD) Moat Score — The Moat Index · Buy Like Buffett